Moreover, for chronic periodontitis cases, higher cost was expended as disease severity increased (ANOVA, P = 0.022; Table 5).
Rather than increasing confidence, high R&D increases uncertainty about future costs, mainly because it improves the base case (low cost) outcomes more than it improves the worst case (high cost) outcomes.
Furthermore, in doubtful cases, higher costs and irradiation exposure may arise if other unnecessary diagnostic imaging methods are ordered.
In addition to the previously mentioned case of "high cost" of consensus, a few additional cases may deserve similar consideration: Chr2-Set2 (144.8–167.7); Chr7-Set3(158.3–166.4); and Chr7-Set3(191.7–200.6) (see Figure 6, C E, and Table S3).
In cases of low costs or high sustainability, participants were more willing to invest in a company that favored non-shareholding over shareholding stakeholders (thereby deciding against their immediate financial interests), while the opposite was true in cases of high costs or low sustainability.
Independent data sets are easily produced in the synthetic case, but at high cost in the case of real data.
This difference may be explained by that some cases associated with high cost and need for intensive care (e.g. many cases of colic and diarrhoea) are in general not treated at the ATG Equine Clinics (i.e. they were day-clinics without provision of longer term hospital care) whereas such cases will almost invariably be captured by insurance data on insured horses.
Due to the small number of cases and the high cost of implants, other therapeutic options must be chosen when the above-mentioned criteria are not met.
Even though only 0.4 5% of the population, these cases induced a high cost for treatment of the individual child.
This is due mainly to lack of health facility data to identify incident cases and the high cost of continuous surveillance of population‐based cohorts required for accurate incidence estimates.
